Search: onr:"swepub:oai:DiVA.org:umu-181664" >
Type IV collagen as...
Type IV collagen as a potential biomarker of metastatic breast cancer
-
- Lindgren, Moa (author)
- Umeå universitet,Kirurgi,Norrlands Universitetssjukhus
-
- Jansson, Malin (author)
- Umeå universitet,Kirurgi,Norrlands Universitetssjukhus
-
- Tavelin, Björn (author)
- Umeå universitet,Onkologi
-
show more...
-
- Dirix, Luc (author)
- Translational Cancer Research Unit, GZA Hospital Sint Augustinus and Antwerp University, Antwerp, Belgium
-
- Vermeulen, Peter (author)
- Translational Cancer Research Unit, GZA Hospital Sint Augustinus and Antwerp University, Antwerp, Belgium
-
- Nyström, Hanna, 1980- (author)
- Umeå universitet,Wallenberg centrum för molekylär medicin vid Umeå universitet (WCMM),Kirurgi,Translational Cancer Research Unit, GZA Hospital Sint Augustinus and Antwerp University, Antwerp, Belgium; Norrlands Universitetssjukhus
-
show less...
-
(creator_code:org_t)
- 2021-03-03
- 2021
- English.
-
In: Clinical and Experimental Metastasis. - : Springer. - 0262-0898 .- 1573-7276. ; 38:2, s. 175-185
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://umu.diva-por... (primary) (Raw object)
-
https://link.springe...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- No reliable, non-invasive biomarker of metastatic breast cancer (mBC) exists: circulating CA15-3 (cCA15-3) is the marker mostly used to monitor mBC. Circulating collagen IV (cCOLIV) has been evaluated in other metastatic cancers and has been found to be a promising biomarker. The overarching aim of this study was to evaluate cCOLIV as a potential biomarker in patients with mBC. The first aim was to determine the levels of cCOL IV and cCA15-3 in patients with healthy controls, primary breast cancer (pBC) and mBC. The second aim was to compare levels of cCOLIV and cCA15-3 in patients with different metastatic sites of BC. The third aim was to investigate the prognostic value of cCOLIV and cCA15-3 for mBC patients. The fourth aim was to analyse whether a combination of the two biomarkers was more accurate in detecting mBC than a single marker. Lastly, we investigated the tissue expression levels of COLIV in BC bone metastases (BM) and liver metastases (LM). Plasma levels of cCOLIV and cCA15-3 from healthy controls and patients with pBC and mBC were measured. COLIV expression in tissue from patients with LM and BM was analysed using immunohistochemistry. Clinical and survival data were collected from medical charts. The levels of cCOLIV and cCA15-3 were significantly elevated in mBC patients compared with healthy controls and pBC patients. No differences in cCOLIV and cCA15-3 levels were found based on the metastatic site. High levels of cCOLIV, but not cCA15-3, correlated with poorer survival. cCOLIV alone and the combination of cCA15-3 and cCOLIV were superior to cCA15-3 at detecting mBC. COL IV was highly expressed in the tissue of LM and BM. Our study suggests that cCOLIV is a potential marker to monitor patients with BC.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- Biomarkers
- Breast cancer
- CA 15-3
- Collagen IV
- Metastases
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database